Literature DB >> 28716894

Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Risks of Incomplete Immunity to Dengue Virus Revealed by Vaccination.

Stephen S Whitehead1, Kanta Subbarao1.   

Abstract

Immune enhancement of dengue disease continues to be a concern for those with incomplete immunity in endemic areas. Advanced testing and follow-up of a newly available live attenuated dengue vaccine has recently shown the ability of vaccination to predispose some recipients for a severe outcome on subsequent infection. To improve safety, recommendations have been made to restrict use of the vaccine to those who are likely to have had prior exposure to dengue virus (DENV). Researchers continue to investigate dengue immunity and seek evidence that dengue vaccines can be safely administered to all populations needing protection.
Copyright © 2018 Cold Spring Harbor Laboratory Press; all rights reserved.

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 28716894      PMCID： PMC5983189          DOI： 10.1101/cshperspect.a028811

Source DB:  PubMed          Journal:  Cold Spring Harb Perspect Biol        ISSN： 1943-0264            Impact factor:   10.005


  26 in total

1.  Safety and immunogenicity of three tetravalent dengue vaccine formulations in healthy adults in the USA.

Authors:  Gustavo H Dayan; Manoj Thakur; Mark Boaz; Carol Johnson
Journal:  Vaccine       Date:  2013-09-07       Impact factor: 3.641

Review 2.  Trials and tribulations on the path to developing a dengue vaccine.

Authors:  Stephen J Thomas; Alan L Rothman
Journal:  Vaccine       Date:  2015-06-27       Impact factor: 3.641

3.  A prospective study of dengue infections in Bangkok.

Authors:  D S Burke; A Nisalak; D E Johnson; R M Scott
Journal:  Am J Trop Med Hyg       Date:  1988-01       Impact factor: 2.345

4.  Dengue Vaccine Efficacy: Not a Zero Sum Game.

Authors:  Scott B Halstead
Journal:  J Infect Dis       Date:  2016-09-29       Impact factor: 5.226

5.  Population Perspectives and World Health Organization Recommendations for CYD-TDV Dengue Vaccine.

Authors:  Annelies Wilder-Smith; Kirsten S Vannice; Joachim Hombach; Jeremy Farrar; Terry Nolan
Journal:  J Infect Dis       Date:  2016-08-05       Impact factor: 5.226

6.  A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response.

Authors:  Anna P Durbin; Beth D Kirkpatrick; Kristen K Pierce; Marya P Carmolli; Cecilia M Tibery; Palmtama L Grier; Noreen Hynes; Kari Opert; Adrienne P Jarvis; Beulah P Sabundayo; Benjamin D McElvany; Eli A Sendra; Catherine J Larsson; Matthew Jo; Janece M Lovchik; Catherine J Luke; Mary C Walsh; Ellen A Fraser; Kanta Subbarao; Stephen S Whitehead
Journal:  J Infect Dis       Date:  2016-02-16       Impact factor: 5.226

Review 7.  Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine.

Authors:  Anna P Durbin; Beth D Kirkpatrick; Kristen K Pierce; Alexander C Schmidt; Stephen S Whitehead
Journal:  Vaccine       Date:  2011-07-21       Impact factor: 3.641

8.  The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes.

Authors:  Daniela Weiskopf; Michael A Angelo; Derek J Bangs; John Sidney; Sinu Paul; Bjoern Peters; Aruna D de Silva; Janet C Lindow; Sean A Diehl; Stephen Whitehead; Anna Durbin; Beth Kirkpatrick; Alessandro Sette
Journal:  J Virol       Date:  2014-10-15       Impact factor: 5.103

9.  A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults.

Authors:  Dennis Morrison; Thomas J Legg; Christopher W Billings; Remi Forrat; Sutee Yoksan; Jean Lang
Journal:  J Infect Dis       Date:  2010-02-01       Impact factor: 5.226

10.  The global distribution and burden of dengue.

Authors:  Samir Bhatt; Peter W Gething; Oliver J Brady; Jane P Messina; Andrew W Farlow; Catherine L Moyes; John M Drake; John S Brownstein; Anne G Hoen; Osman Sankoh; Monica F Myers; Dylan B George; Thomas Jaenisch; G R William Wint; Cameron P Simmons; Thomas W Scott; Jeremy J Farrar; Simon I Hay
Journal:  Nature       Date:  2013-04-07       Impact factor: 49.962
View more
  7 in total

1.  A Combination of Two Human Monoclonal Antibodies Prevents Zika Virus Escape Mutations in Non-human Primates.

Authors:  Jennifer R Keeffe; Koen K A Van Rompay; Priscilla C Olsen; Qiao Wang; Anna Gazumyan; Stephanie A Azzopardi; Dennis Schaefer-Babajew; Yu E Lee; Jackson B Stuart; Anil Singapuri; Jennifer Watanabe; Jodie Usachenko; Amir Ardeshir; Mohsan Saeed; Marianna Agudelo; Thomas Eisenreich; Stylianos Bournazos; Thiago Y Oliveira; Charles M Rice; Lark L Coffey; Margaret R MacDonald; Pamela J Bjorkman; Michel C Nussenzweig; Davide F Robbiani
Journal:  Cell Rep       Date:  2018-11-06       Impact factor: 9.423

2.  Dengue-specific CD8+ T cell subsets display specialized transcriptomic and TCR profiles.

Authors:  Yuan Tian; Mariana Babor; Jerome Lane; Grégory Seumois; Shu Liang; N D Suraj Goonawardhana; Aruna D De Silva; Elizabeth J Phillips; Simon A Mallal; Ricardo da Silva Antunes; Alba Grifoni; Pandurangan Vijayanand; Daniela Weiskopf; Bjoern Peters; Alessandro Sette
Journal:  J Clin Invest       Date:  2019-03-18       Impact factor: 14.808

3.  Biomimetic inorganic camouflage circumvents antibody-dependent enhancement of infection.

Authors:  Xiaoyu Wang; Yong-Qiang Deng; Dong Yang; Yun Xiao; Hui Zhao; Qing-Gong Nian; Xurong Xu; Xiao-Feng Li; Ruikang Tang; Cheng-Feng Qin
Journal:  Chem Sci       Date:  2017-10-20       Impact factor: 9.825

4.  Dengue envelope-based 'four-in-one' virus-like particles produced using Pichia pastoris induce enhancement-lacking, domain III-directed tetravalent neutralising antibodies in mice.

Authors:  Ravi Kant Rajpoot; Rahul Shukla; Upasana Arora; Sathyamangalam Swaminathan; Navin Khanna
Journal:  Sci Rep       Date:  2018-06-05       Impact factor: 4.379

Review 5.  Chikungunya as a paradigm for emerging viral diseases: Evaluating disease impact and hurdles to vaccine development.

Authors:  Giovanni Rezza; Scott C Weaver
Journal:  PLoS Negl Trop Dis       Date:  2019-01-17

Review 6.  Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era?

Authors:  Jedhan Ucat Galula; Gielenny M Salem; Gwong-Jen J Chang; Day-Yu Chao
Journal:  Hum Vaccin Immunother       Date:  2019-08-23       Impact factor: 3.452

7.  An intermolecular-split G-quadruplex DNAzyme sensor for dengue virus detection.

Authors:  Jeunice Ida; Akinori Kuzuya; Yee Siew Choong; Theam Soon Lim
Journal:  RSC Adv       Date:  2020-09-07       Impact factor: 4.036
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.